PMHNP Scope of Practice for General Psychiatry in Georgia

If you’re a psychiatrist, PMHNP, or prescriber wondering whether you can legally prescribe ADHD medications, benzodiazepines, or other controlled substances through telehealth — you’re not alone. This is the most common compliance question we hear from mental health providers in 2026.

The short answer: Yes, you can — for now. Federal telehealth flexibilities have been extended through December 31, 2026, allowing you to prescribe Schedule II-V medications via video consultation without an initial in-person exam. But the rules are changing, state laws add layers of complexity, and the ‘for now’ part matters more than you might think.

Let’s cut through the confusion with what you actually need to know to practice compliantly and confidently.

The Current State of Play: Extended Flexibilities Through 2026

As of January 2, 2026, the DEA and HHS announced their fourth temporary extension of COVID-era telehealth prescribing rules. This means you can continue prescribing controlled substances (Schedules II-V) via telemedicine without requiring patients to have an initial in-person visit — at least through the end of this year.

What this means for your practice:

• You can evaluate new ADHD patients via video and prescribe stimulants like Adderall or Vyvanse
• Anxiety patients can start benzodiazepines after a thorough telehealth assessment
• You can initiate buprenorphine for opioid use disorder through telemedicine
• Follow-up medication management can continue entirely via telehealth

The catch: These are temporary rules while the DEA finalizes permanent regulations. The landscape will shift — likely in 2026 or early 2027 — and you need to be prepared.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: The DEA’s Proposed Permanent Rules

In January 2025, the DEA proposed three new rules that will reshape telehealth prescribing once finalized:

1. Special Telemedicine Registration for Psychiatrists

This is the big one for mental health providers. The DEA is creating a Special Telemedicine Prescriber Registration that would allow qualified providers to prescribe controlled substances to new patients via telehealth without any in-person exam.

For Schedule II substances (stimulants, some pain meds), eligibility is initially limited to:

• Board-certified psychiatrists
• Hospice/palliative care physicians
• Long-term care facility physicians
• Pediatricians (limited cases)

For Schedule III-V substances, any qualified prescriber could apply for this registration.

What this means: If you’re a board-certified psychiatrist, you’ll likely be able to continue tele-prescribing ADHD medications indefinitely — you’ll just need to obtain an additional DEA registration and comply with new oversight requirements (like checking a national PDMP and possibly submitting annual reports).

2. Buprenorphine Rule (6-Month Allowance)

For providers treating opioid use disorder, the proposed rule would allow:

• Initiating buprenorphine via telehealth (including audio-only)
• Continuing treatment for up to 6 months before requiring an in-person evaluation
• After 180 days, an in-person visit would be required for ongoing treatment

This is more generous than current law and recognizes how telehealth has improved access to addiction treatment.

3. Platform Registration & National PDMP

Online telehealth platforms would be required to register with the DEA for the first time. A national Prescription Drug Monitoring Program would also be established to track controlled substance prescriptions across state lines and reduce diversion.

This is the DEA’s response to well-publicized cases of telehealth companies over-prescribing stimulants. Expect more oversight and accountability for platforms — which ultimately protects good providers.

The Economics: Why Telehealth Platforms Make Sense

Here’s the reality most providers don’t discuss: acquiring psychiatric patients through DIY marketing is expensive and uncertain.

Traditional marketing costs:

• Google Ads for mental health keywords: $15-40+ per click
• Realistic cost per booked patient through PPC: $200-400+
• SEO investment: 6-12 months before meaningful results, thousands in monthly spend
• Psychology Today and directory listings: Monthly fees + you compete with hundreds of providers
• Agency/consultant fees, staff time for lead qualification, no-shows from cold leads

When you factor in ALL costs — ad testing, optimization, months of investment before ROI, failed campaigns — a qualified psychiatric patient costs $200-500+ to acquire through DIY channels.

The platform model alternative:

Instead of spending $3,000-5,000/month on marketing with uncertain results, platforms like Klarity Health use a pay-per-appointment model. You pay a standard listing fee only when a pre-qualified patient books with you.

The value proposition:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule — only pay when you see patients

This is guaranteed ROI vs. gambling on marketing channels. For providers starting out or scaling, removing the patient acquisition risk entirely makes economic sense.

State-by-State Rules: Where It Gets Complicated

Federal rules set the floor, but states can impose stricter requirements. Here’s what matters in key states:

Florida: The Psychiatric Exception

Florida explicitly prohibits Schedule II controlled substance prescribing via telehealth — except for:

• Psychiatric disorder treatment
• Inpatient hospital care
• Hospice care
• Nursing home residents

What this means: You CAN prescribe Adderall for ADHD via telehealth in Florida (it’s psychiatric treatment), but you must document the psychiatric indication clearly. You cannot prescribe opioids for chronic pain via telehealth.

Florida also offers an out-of-state telehealth provider registration that lets non-Florida-licensed providers practice telemedicine with Florida patients — but you’re still bound by Florida’s prescribing rules.

Compliance requirements:

• Check Florida’s E-FORCSE PDMP before prescribing any controlled substance to patients 16+
• E-prescribe all controlled substances (required since 2021)
• If prescribing for chronic pain, designate yourself as a controlled substance prescriber on your DOH profile

Texas: NP Restrictions & Pain Management Rules

Texas recognizes telehealth-established patient relationships without in-person exams (since 2017), but has specific limitations:

For PMHNPs: Texas law prohibits NPs from prescribing Schedule II controlled substances outside hospital or hospice settings. This means:

• A Texas PMHNP cannot prescribe Adderall, Ritalin, or other ADHD medications in outpatient telepsychiatry
• Any patient needing Schedule II must be managed by a physician
• NPs can prescribe Schedule III-V (most anxiety meds, sleep aids, etc.) under physician delegation

For all providers:

• Cannot prescribe controlled substances for chronic pain via telehealth without an in-person exam
• Must check Texas PMP before prescribing opioids, benzodiazepines, barbiturates, or carisoprodol
• NPs must always practice under physician supervision (restricted practice state)

California: PMHNP Independence & CURES

California is transitioning to full practice authority for experienced PMHNPs:

• NPs with ≥3 years experience can practice in group settings without physician supervision (as of 2023)
• By 2026, experienced NPs can open independent practices (Category 104 license)

Compliance requirements:

• Check CURES PDMP before first prescribing Schedule II-IV and every 4 months for ongoing treatment
• 100% e-prescribing mandate (since January 2022)
• No state restrictions on telehealth prescribing of controlled substances beyond federal law

New York: Strict PDMP & E-Prescribing

New York allows experienced PMHNPs (>3,600 hours) to practice independently, including prescribing controlled substances via telehealth.

Compliance requirements:

• Check I-STOP PMP registry before every Schedule II, III, or IV prescription
• All prescriptions must be e-prescribed (mandate since 2016 — one of the strictest in the nation)
• No in-person exam required by state law; video consultation establishes valid patient relationship

Pennsylvania: Collaboration Requirements

Pennsylvania requires PMHNPs to have written collaborative agreements with physicians (at least two for prescriptive authority).

Key points:

• No comprehensive telehealth statute yet (practice under general medical regulations)
• Video exam can establish patient relationship
• Must check PA PDMP before prescribing opioids or benzodiazepines
• E-prescribing required for controlled substances (since October 2019)
• Schedule II limited to 30-day supply under NP collaboration; Schedule III-IV up to 90 days

Illinois: Full Practice Pathway with Caveats

Illinois PMHNPs can obtain Full Practice Authority (FPA) after 4,000 hours of experience and 250 hours of additional training.

Important limitation: Even with FPA, Illinois NPs must have a physician consultation relationship for prescribing benzodiazepines or Schedule II medications, with prescriptions limited to 30-day supplies.

Compliance:

• Check IL PMP before each opioid prescription
• E-prescribing required for all controlled substances (since January 2023)
• Standard of care applies to telehealth (no special state restrictions)

Psychiatrist vs PMHNP: Scope of Practice Reality

Psychiatrists (MD/DO) have full independent prescriptive authority in all states. If you’re a board-certified psychiatrist, your scope is uniform — the only variables are state telehealth rules and licensing requirements.

PMHNPs face a patchwork of state regulations:

What this means for platform providers:

If you’re a PMHNP joining a telehealth platform, you need to understand your state’s rules. Some states require the platform to provide a collaborating physician. Others allow complete independence. This affects your operational model and earning potential.

Ryan Haight Act: What You Need to Know

The Ryan Haight Act (2008) technically requires at least one in-person evaluation before prescribing controlled substances via the internet. But it has been suspended under federal emergency exceptions since March 2020, with extensions now running through December 31, 2026.

Current interpretation:

• If a patient was ever seen in person by any provider, you can prescribe controlled medications via telehealth with no additional requirements
• For new patients never seen in person, current telehealth prescribing is allowed under the temporary extension
• Once permanent DEA rules take effect, you’ll likely need either an in-person visit or the special telemedicine registration for ongoing prescribing to new patients

What hasn’t changed: You still need a valid patient-provider relationship established through an appropriate evaluation. A questionnaire-only assessment doesn’t cut it — you need real-time, interactive consultation (preferably video).

Federal Compliance Requirements Beyond DEA Rules

1. MATE Act Training (8 Hours Required)

As of June 2023, all prescribers must complete 8 hours of training on substance use disorder and appropriate prescribing before DEA registration renewal. This is mandated by the Medication Access and Training Expansion (MATE) Act.

Exemptions:

• Board-certified addiction psychiatrists (specialty credential counts)
• Providers whose training already included equivalent education

If you haven’t done this yet and your DEA registration is up for renewal, you need to complete it.

2. X-Waiver Eliminated (Good News)

The DATA 2000 ‘X-waiver’ requirement was eliminated in 2023. Any DEA-registered psychiatrist or NP can now prescribe buprenorphine for opioid use disorder without a special waiver.

In exchange, you must complete the MATE Act training described above.

3. E-Prescribing

Federal law (SUPPORT Act) requires controlled substances under Medicare Part D to be e-prescribed. Most states also mandate e-prescribing with limited exceptions.

Your e-prescribing system must be DEA-compliant with two-factor authentication. Telehealth platforms typically handle this automatically.

4. HIPAA Compliance

Using a secure, HIPAA-compliant telehealth platform is non-negotiable. Consumer video apps (Zoom free, FaceTime, etc.) don’t meet the requirements for healthcare.

Best Practices for Compliant Telehealth Prescribing

1. Document thoroughly

• Full psychiatric history
• Detailed mental status exam (even via video you can assess appearance, speech, mood, thought process)
• Review of prior treatments and medications
• Assessment of risk factors (substance use history, diversion risk)
• Clear documentation of diagnosis and treatment rationale

2. Check your PDMP every timeMost states require checking the prescription monitoring database before prescribing controlled substances. Even if not legally required, it’s standard of care and protects you from liability.

3. Use real-time video for initial evaluationsAudio-only may be acceptable for follow-ups with established patients, but initial controlled substance prescribing should be done via interactive video consultation. This meets the highest standard of care and aligns with what the DEA expects.

4. Set appropriate limits

• Start with shorter prescription durations for new patients (30 days is standard)
• Require follow-ups before refills
• Establish clear treatment agreements for controlled substances
• Have protocols for urine drug screens when clinically indicated (even via telehealth, you can order labs)

5. Stay within your scope and trainingIf you’re treating complex addiction, co-occurring disorders, or medication-resistant cases, ensure you have appropriate training and consultation available. The standard of care for telehealth is the same as in-person.

6. Know when to refer for in-person careSome situations require in-person evaluation:

• Acute safety concerns or suicidal ideation requiring immediate intervention
• Complex medical comorbidities affecting medication choice
• Treatment-resistant cases where you need more diagnostic clarity
• Medication management that requires physical exams or monitoring (e.g., lithium requires periodic labs)

FAQ: Top Questions Psychiatrists Ask About Telehealth Prescribing

Can I prescribe Adderall to a new patient via telehealth in 2026?

Yes, under current federal rules (extended through December 31, 2026). You must conduct a thorough evaluation via real-time video, document appropriately, check the PDMP, and follow state-specific requirements. Once the DEA finalizes permanent rules (likely 2026-2027), board-certified psychiatrists will likely need a special telemedicine registration but can continue prescribing Schedule II via telehealth.

Do I need an in-person visit before prescribing benzodiazepines?

Not under current federal rules. However, check your state law — some states may have additional requirements. Best practice: use video consultation for the initial evaluation and document a thorough assessment including risk factors for dependence.

What happens when the DEA extension expires at the end of 2026?

The DEA is expected to finalize permanent rules before or around that time. Most likely outcome: psychiatrists will be able to continue telehealth prescribing with additional registration and compliance requirements. Stay alert for DEA announcements in late 2026.

Can I prescribe controlled substances via telehealth if I’m licensed in multiple states?

Yes, but you must follow the rules of each state where your patients are located. You need:

• A medical license in each state
• A DEA registration for each state
• Registration with each state’s PDMP
• Compliance with each state’s specific telehealth and prescribing laws

As a PMHNP, can I prescribe ADHD medications via telehealth?

It depends on your state:

• In full practice states (NY, some others): Yes, independently after meeting experience requirements
• In reduced practice states (PA, IL): Yes, but you need a physician collaboration agreement and may have prescription limits
• In restricted practice states (TX, FL): No for outpatient Schedule II (Texas), or only under close physician supervision (Florida)

Do audio-only phone visits count for prescribing controlled substances?

Currently, the DEA extension allows audio-video consultation. Audio-only is specifically permitted for buprenorphine under the proposed OUD rule, but for other controlled substances, standard of care strongly favors video for initial evaluations. Follow-ups with established patients may be acceptable by phone depending on clinical judgment and state law.

How do I check if my malpractice insurance covers telehealth?

Contact your carrier directly. Most policies now include telehealth coverage, but verify that it extends to all states where you practice and covers controlled substance prescribing. Some carriers require notification when you start telehealth practice.

What documentation do I need for the PDMP check?

Most states require you to document in the medical record that you checked the PDMP, when you checked it, and any findings relevant to prescribing decisions (e.g., ‘PDMP reviewed, no concerning findings’ or ‘PDMP shows concurrent benzodiazepine prescription from another provider; discussed with patient’).

Can I prescribe buprenorphine for opioid use disorder via telehealth?

Yes. Under current federal rules and the proposed permanent buprenorphine rule, you can initiate and manage buprenorphine treatment entirely via telehealth (even audio-only) for up to 6 months before requiring an in-person visit. No X-waiver is required (that was eliminated in 2023), but you must complete MATE Act training.

What’s the penalty for non-compliance with telehealth prescribing rules?

Violations can result in:

• DEA license suspension or revocation
• State medical board discipline (license suspension, fines, mandatory monitoring)
• Criminal charges in egregious cases (especially if diversion or fraud is involved)
• Civil liability and malpractice exposure

The key is following both federal and state rules, documenting appropriately, and always practicing within the standard of care.

The Bottom Line: Focus on Care, Not Compliance Anxiety

The regulatory landscape for telehealth prescribing is complex, but it’s also more permissive than many providers realize. As a psychiatrist or psychiatric prescriber in 2026, you can:

✅ Evaluate new patients via video and prescribe controlled substances (through December 2026, likely beyond with registration)✅ Manage ADHD, anxiety, depression, and other psychiatric conditions entirely via telehealth✅ Provide buprenorphine treatment for opioid use disorder without special waivers✅ Practice across state lines if properly licensed

What you need:

• Understanding of federal DEA rules (current extension + proposed changes)
• Knowledge of specific state requirements where your patients are located
• Solid documentation and clinical practices
• Use of compliant telehealth platforms
• Regular PDMP checks and e-prescribing

Where platforms like Klarity Health help:

Instead of navigating patient acquisition, credentialing, telehealth platforms, billing, and compliance solo, a platform handles the infrastructure. You focus on clinical care. You see pre-qualified patients who need your expertise. You pay only for completed appointments — no wasted marketing spend, no months waiting for SEO results, no risk.

Whether you’re a newly minted PMHNP in a full-practice state looking to build a patient panel, or an experienced psychiatrist wanting to scale your practice without the overhead of traditional marketing, understanding these regulations gives you the confidence to practice compliantly while maximizing your time with patients.

The rules will continue evolving. The DEA will finalize permanent regulations. States will adjust their laws. But the fundamentals remain: thorough evaluation, appropriate documentation, checking safeguards like PDMPs, and following both federal and state rules.

Ready to expand your telepsychiatry practice without the patient acquisition headaches?

Klarity Health provides the platform, patients, and infrastructure so you can focus on what you do best — delivering high-quality psychiatric care. No upfront costs. No monthly fees. Just qualified patients matched to your availability and specialty.

[Learn more about joining Klarity’s provider network →]

Sources & References

1. U.S. Department of Health and Human Services Press Release: ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ (January 2, 2026) – hhs.gov

2. U.S. Drug Enforcement Administration Press Release: ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Medications’ (January 16, 2025) – dea.gov

3. Substance Abuse and Mental Health Services Administration: ‘MAT Act Waiver Elimination and Training Requirements’ (Updated 2023) – samhsa.gov

4. Akerman LLP Legal Analysis: ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth’ (March 2023) – akerman.com

5. Tebra (The Intake): ‘Nurse Practitioner Laws by State: A Comprehensive 2025 Guide’ (Updated December 4, 2025) – tebra.com

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Telehealth and controlled substance prescribing regulations continue to evolve. Always consult your state medical board, DEA guidelines, and legal counsel for specific compliance questions related to your practice.

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices